Merck may nonetheless be a profitable inventory, regardless of the pharmaceutical firm’s current transfer to reprice one in all its medicines, Virtus Funding Companions chief market strategist Joe Terranova informed CNBC’s ” Halftime Report ” on Monday. Terranova instructed he’s nonetheless bullish on the inventory, even after the agency agreed final yr to cut back the value of diabetes medicine Januvia to $100 from $330 for sufferers utilizing the TrumpRx platform. “I consider in Merck,” Terranova mentioned Monday. “They report tomorrow morning, together with Pfizer , [so] we will hear loads about how the agreements with the president on decreasing the fee … [of certain drugs is] affecting them.” MRK 3M mountain Merck shares are up greater than 30% over the previous three months. Wall Road analysts predict Merck will earn $2.01 per share on income of $16.2 billion within the fourth quarter, in keeping with FactSet information. Merck’s inventory has had a stable run, popping roughly 32% over the previous three months. That is regardless of the strain on drug costs, which have raised questions on its valuation. Additionally talks to amass biotech agency Revolution Medicines fell aside final month, per The Wall Road Journal . Terranova mentioned he had been including different biotech and pharmaceutical names to the agency’s portfolio, together with Gilead Science , Eli Lilly and Regeneron because the sector positive aspects floor. The S & P 500 Well being Care index has added 8% over the previous three months.